
Vyvgart gMG Label Expansion: Triple Seronegative Subtypes
An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.
© 2026 IntuitionLabs. All rights reserved.